Lung Cancer Dispatch
4.6K views | +0 today
Follow
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Suggested by Cancer Commons
Scoop.it!

New Drug Shrinks NSCLC Tumors, But Does Not Improve Survival, Early Results Say

New Drug Shrinks NSCLC Tumors, But Does Not Improve Survival, Early Results Say | Lung Cancer Dispatch | Scoop.it

Results from a phase II clinical trial show that Cerulean Pharma’s anticancer drug, CRLX101, did not increase survival for patients with previously treated non-small cell lung cancer (NSCLC). However, CRLX101 did shrink tumor size. Cerulean took a risk by focusing on overall survival; early clinical trials often measure drug effectiveness by looking at less-challenging measures, such as treatment response rate or time to cancer worsening. Several other clinical trials of CRLX101 in different cancers, including small cell lung cancer (SCLC), are still ongoing. More details about the drug and the trial can be found at: http://www.xconomy.com/boston/2013/03/06/cerulean-pharma-arrives-at-moment-of-truth-with-cancer-drug/.

Cancer Commons's insight:

PR Newswire | Mar 22, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Clinical Trial Will Examine Effectiveness of CRLX101 for Small Cell Lung Cancer

Clinical Trial Will Examine Effectiveness of CRLX101 for Small Cell Lung Cancer | Lung Cancer Dispatch | Scoop.it

Cerulean Pharma Inc. is beginning a phase II clinical trial that will investigate the safety and effectiveness of a novel chemotherapy drug, CRLX101, in patients with extensive-stage small cell lung cancer (SCLC) who have responded to first-line, platinum-based chemotherapy. The study will compare CRLX101 to topotecan (Hycamtin), which is currently the only approved second-line therapy for relapsed SCLC. CRLX101 is already being assessed as a treatment for non-small cell lung cancer (NSCLC) in another phase II trial close to completion, and may be safer than Hycamtin.

Cancer Commons's insight:

News-Medical.Net | Jan 31, 2013

more...
No comment yet.